about
The association between TGF-β1 polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: a meta-analysis.Quercetin liposomes protect against radiation-induced pulmonary injury in a murine model.Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma.Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study.Implementation of single-breath-hold cone beam CT guided hypofraction radiotherapy for lung cancerEfficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reportsSafety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study.EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.Ionizing Radiation-Induced Cellular Senescence in Normal, Non-transformed Cells and the Involved DNA Damage Response: A Mini Review.PD-1/PD-L1 Inhibitors in Cervical CancerAdvancements and Obstacles of CRISPR-Cas9 Technology in Translational ResearchApplications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor CancersRethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapyCrizotinib versus chemotherapy: a real-world cost-effectiveness study in ChinaA phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLCSafety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerPublisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
P50
Q35123851-40B4FD24-8F85-4250-82E5-DFBB7927DF30Q37211831-B55EE0BC-4C66-42E5-A5B1-56A68129BC79Q37388685-6AB08A08-6A08-4475-85DD-57555C771F78Q37590580-22C91C6B-8CCE-485B-92D7-00A3093CC38DQ37714830-40DA87A8-8BA9-4879-AC62-195A5EAABD4CQ41472672-940A40FB-9066-4EF5-B855-CE837CC6F058Q50050078-78143D5E-EF81-4AD6-B277-CFFC532FA58DQ50568765-40539F47-E1F0-47A0-BA9F-AC35C5830F1FQ52589567-5C674E49-0BD1-46D8-BD8C-A1EF9A7C1110Q55267324-77E31578-A34E-4D72-A677-49CF265C261DQ61803811-92BF1D32-0BAC-4FBA-AE4C-46A87F79DC12Q64089162-736E31C4-BC15-4654-9425-FE2A73FA8442Q90298709-D5E7E63C-87C4-40BE-A087-90B8850AA5EAQ92074701-79F230CB-5658-4D9F-9D3A-A9475498EF33Q92776572-A3B119A1-FA42-48E2-8D4E-2395DB44B578Q92973368-EA32E01D-3EC6-4F08-841F-3EADBBBDA494Q93271196-F75B2B23-30FE-4DAC-8D18-7DE897AE8393Q96577068-DA1AE366-3C97-4F3D-ACAD-24BA5D2EE1C4
P50
description
researcher (ORCID 0000-0003-1671-1408)
@en
name
You Lu
@en
type
label
You Lu
@en
prefLabel
You Lu
@en
P31
P496
0000-0003-1671-1408